Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC12115 Adrenomedullin (AM) (1-52), human TFA (Human adrenomedullin-(1-52)-NH2 (TFA)) Adrenomedullin (AM) (1-52), human (TFA) affects cell proliferation and angiogenesis in cancer.
DC20645 ADT-094 ADT-094 (ADT094) is a novel, non-COX inhibitory sulindac derivative that potently and selectivity inhibits colon tumor cell growth by inhibiting PDE5 and PDE10 with IC50 of 2.4 uM and 0.5 uM, respectively.
DC11097 ADX-102 (Reproxalap;NS-2) Featured ADX-102 (Reproxalap, NS-2) is a novel small molecule immunomodulator that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain; DX-102 is a promising agent for the treatment of dry eye disease.
DC5113 AEE-788 (NVP-AEE788) Featured AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.
DC23140 AF38469 Featured AF38469 is a potent, selective, orally bioavailable Sortilin inhibitor with IC50 of 330 nM, shows no activity against the NTR1 receptor as well as a panel of targets known to bind acidic molecules (δ-Opioid, GPR40, PPARδ, EP1, Angiotensin AT1, Endothelin
DC12539 AF40431 AF40431 (AF-40431) is the first reported small-molecule ligand of the VPS10P family sorting receptor Sortilin with IC50 of 4.4 uM, binds in the neurotensin-binding site of sortilin..
DC23642 AF-792 AF-792 (RO-5) is a novel selective P2X3 and P2X2/3 antagonist with pIC50 of 8.2 and 7.9 respectively, with no inhibition at other P2X receptors.
DC20108 Afegostat D-Tartrate (D-Isofagomine (D-Tartrate); Isofagomine (D-Tartrate)) Afegostat D-Tartrate is a pharmacological chaperone, which specifically and reversibly binds acid-β-glucosidase (GCase) in the endoplasmic reticulum (ER) with high affinity.
DC8507 AG13958 AG13958 is a VEGF inhibitor that was clinical development by Pfizer in 2006-07 for treatment of age-related macular degeneration (AMD).
DC7164 AG-024322 AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models. The no-adverse-effect dose of AG-024322 was 2 mg/kg and associated with ov
DC12499 AG-270 Featured AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM.
DC12196 Aganepag (AGN 210937) Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.
DC21990 AGI-14100 AGI-14100 (AGI14100) is a novel potent and selective, orally available IDH1 mutant inhibitor.
DC12225 AGL-2263 AGL-2263 is an insulin receptor (IR) blocker.
DC7767 AGN 194310 AGN 194310(VTP-194310) is a potent and selective pan-RARs agonist with Kd values of 3/2/5 nM for RARα/β/γ respectively.
DC12213 AGN 210676 (Simenepag) AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.
DC11005 AGN192836 AGN192836 (AGN 192836) is a potent, selective α2 adrenergic (alpha 2-adrenoceptor) agonist with EC50 of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.
DC3171 Agomelatine Agomelatine is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor.
DC20304 AGPS-IN-1a AGPS-IN-1a is a potent inhibitor of the ether lipid-generating enzyme alkyl-glycerone phosphate synthase (AGPS), selectively lowers ether lipid levels in several types of human cancer cells and impairs their cellular survival and migration..
DC12535 AgrA inhibitor F19 AgrA inhibitor F19 is a small-molecule AgrA inhibitor that act as antivirulence agent against Gram-positive pathogens, blocks staphylococcal transcription factor AgrA from binding to its promoter and inhibits toxin and virulence factor transcription.
DC8734 AHU-377(Sacubitril) AHU-377 is an inhibitor of neprilysin with IC50 value of 5 nM.
DC20305 AI-10-104 Featured AI-10-104 is a small molecule inhibitor that interferes with CBFβ binding to RUNX proteins with IC50 of 1.25 uM in FRET assays.
DC9402 Letermovir(AIC-246) Featured AIC246 is a novel anti-CMV compound which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors.
DC23900 AICAR phosphate Featured AICAR phosphate (Acadesine, AICA Riboside, NSC 105823) is a selective AMPK activator in both hepatocytes and adipocytes.
DC12402 AJM300 AJM300 (AJM 300, AJM-300) is a novel potent, selective, oraaly available alpha 4 integrin antagonist fortreatment of active ulcerative colitis..
DC23660 AK106-001616(AK 106-001616) AK106-001616 (AK 106-001616) is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) with IC50 of 3.8 nM (human cPLA2 enzyme).
DC21991 AK306 AK306 is a small molecule clathrin heavy chain (CLTC/CHC) binding compound that induces arrest and apoptosis of the HCT116 colon cancer cell line with EC50 of 50 nM.
DC23789 AK778 Featured AK778 (Col001) is a small-molecule compound that inhibits the interaction of Hsp47 with collagen, competitively inhibits the interaction and causes the inhibition of collagen secretion by destabilizing the collagen triple helix. .
DC12158 AKOS B018304 Featured AKOS B018304 is an arylalkylidene derivative, with polar substitution at para-position.
DC10941 AKR1C3 inhibitor KV-37 AKR1C3 inhibitor KV-37 is a potent, isoform selective and metabolically stable inhibitor of Aldo-keto reductase 1C3 (AKR1C3) with IC50 of 66 nM, displays 109-fold selectivity over AKR1C2.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>